Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening
Strategic Profile
The company is focusing on a next-generation screening test with mRNA biomarkers that detects both colorectal cancer and advanced adenomas, seeking reimbursement and guideline inclusion. Mainz Biomed has a collaboration agreement with Thermo Fisher Scientific for colorectal cancer screening product development and commercialization. In 2025, the company entered into a licensing agreement with Liquid Biosciences for mRNA biomarkers enabling a blood-based pancreatic cancer screening test for potential FDA applications.
Cyborg Score Rationale
The company faces cash constraints typical of micro-cap biotech, with a $3 million August 2025 offering representing minimal capital for a diagnostics company with high development costs. However, recent clinical progress and expanding pipeline provide growth potential offset by capitalization pressures.
Top Insights
Next-generation CRC test with mRNA biomarkers demonstrated strong performance; eAArly DETECT 2 study launched in 2025 to validate on average-risk populations for FDA pivotal trial preparation
ColoAlert received MHRA registration for UK market (2025) and added to DoctorBox digital health platform in Germany; expanding European commercial footprint
Pancreatic cancer blood-based screening feasibility study initiated with 95% sensitivity and 98% specificity in early validation; received 50% government funding from German development bank ISB
Capital constraint evidenced by $3M follow-on offering at $1.35/unit (August 2025); withdrawal of FDA Breakthrough Device application to expand clinical dataset suggests regulatory recalibration
Named Competitors
FIT Testing — Fecal immunochemical tests for occult blood screening; globally most-used non-invasive CRC test
Colonoscopy — Gold-standard invasive colorectal cancer screening requiring procedure infrastructure
Check-Cap — Alternative CRC screening solutions competing in non-invasive diagnostics space
Recent Developments
(January 2026) 2025 year-end highlights review; full financial results expected March 2026
(November 2025) Showcased cancer detection solutions at MEDICA 2025; ColoAlert and next-gen diagnostic solutions featured
(June 2025) Pancreatic cancer feasibility study commenced with Crown Bioscience; demonstrated 95% sensitivity, 98% specificity in partnership discovery phase
(August 2025) Priced $3.0M follow-on offering; $1.35/unit at 2.2M units with Series A warrants
Open the full interactive Mainz Biomed N.V. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.